Eric H. Yang, MD
Email: Ehyang@mednet.ucla.edu
In 2016, the UCLA Cardio-oncology Program officially made its debut, actively managing patients undergoing cancer treatments, providing risk stratification, evaluating for and treating cardiotoxicity, as well as providing long term cardiotoxicity surveillance for cancer survivors.
This is a multidisciplinary collaboration across multiple specialties within the Divisions of Cardiovascular Disease and Hematolog/Oncology at UCLA in promoting awareness, research projects in looking at the effects of malignancies and cardiotoxic treatments on both the adult and pediatric populations. I have been the primary cardiology consultant for the UCLA-LIVESTRONG Survivorship Center of Excellence since 2012 and also conducting research projects in looking at the application of multimodality imaging such as echocardiography, cardiac magnetic resonance and cardiac computed tomography in evaluating for short and long-term clinical and subclinical evidence of cardiotoxicity from cancer treatments; this includes, but is not limited to chemotherapy, novel targeted therapies, and radiotherapy.
